vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Eastern Bankshares, Inc. (EBC). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $205.4M, roughly 1.4× COLLEGIUM PHARMACEUTICAL, INC). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs 8.3%, a 13.8% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs 12.9%). Over the past eight quarters, Eastern Bankshares, Inc.'s revenue compounded faster (38.6% CAGR vs 19.1%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
COLL vs EBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $295.9M |
| Net Profit | $17.0M | $65.3M |
| Gross Margin | 62.5% | — |
| Operating Margin | 29.6% | — |
| Net Margin | 8.3% | 22.1% |
| Revenue YoY | 12.9% | 710.6% |
| Net Profit YoY | 35.3% | -34.4% |
| EPS (diluted) | $0.48 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $295.9M | ||
| Q4 25 | $205.4M | $37.5M | ||
| Q3 25 | $209.4M | $241.5M | ||
| Q2 25 | $188.0M | $244.9M | ||
| Q1 25 | $177.8M | $31.1M | ||
| Q4 24 | $181.9M | $216.5M | ||
| Q3 24 | $159.3M | $203.4M | ||
| Q2 24 | $145.3M | $154.0M |
| Q1 26 | — | $65.3M | ||
| Q4 25 | $17.0M | $99.5M | ||
| Q3 25 | $31.5M | $106.1M | ||
| Q2 25 | $12.0M | $100.2M | ||
| Q1 25 | $2.4M | $-217.7M | ||
| Q4 24 | $12.5M | $60.8M | ||
| Q3 24 | $9.3M | $-6.2M | ||
| Q2 24 | $19.6M | $26.3M |
| Q1 26 | — | — | ||
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 29.6% | — | ||
| Q3 25 | 29.7% | 38.9% | ||
| Q2 25 | 18.7% | 41.0% | ||
| Q1 25 | 12.2% | -590.9% | ||
| Q4 24 | 20.9% | 33.3% | ||
| Q3 24 | 21.9% | -1.6% | ||
| Q2 24 | 32.7% | 24.7% |
| Q1 26 | — | 22.1% | ||
| Q4 25 | 8.3% | 265.6% | ||
| Q3 25 | 15.0% | 44.0% | ||
| Q2 25 | 6.4% | 40.9% | ||
| Q1 25 | 1.4% | -699.2% | ||
| Q4 24 | 6.9% | 28.1% | ||
| Q3 24 | 5.9% | -3.0% | ||
| Q2 24 | 13.5% | 17.1% |
| Q1 26 | — | $0.29 | ||
| Q4 25 | $0.48 | $0.48 | ||
| Q3 25 | $0.84 | $0.53 | ||
| Q2 25 | $0.34 | $0.50 | ||
| Q1 25 | $0.07 | $-1.08 | ||
| Q4 24 | $0.36 | $0.29 | ||
| Q3 24 | $0.27 | $-0.03 | ||
| Q2 24 | $0.52 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $551.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $4.3B |
| Total Assets | $1.7B | $30.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $551.7M | ||
| Q4 25 | $386.7M | $507.6M | ||
| Q3 25 | $285.9M | $703.4M | ||
| Q2 25 | $222.2M | $948.3M | ||
| Q1 25 | $197.8M | $609.0M | ||
| Q4 24 | $162.8M | $1.9B | ||
| Q3 24 | $120.0M | $1.7B | ||
| Q2 24 | $271.6M | $1.4B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $301.7M | $4.3B | ||
| Q3 25 | $274.8M | $3.8B | ||
| Q2 25 | $232.2M | $3.7B | ||
| Q1 25 | $234.4M | $3.6B | ||
| Q4 24 | $228.8M | $3.6B | ||
| Q3 24 | $234.3M | $3.7B | ||
| Q2 24 | $216.6M | $3.0B |
| Q1 26 | — | $30.6B | ||
| Q4 25 | $1.7B | $30.6B | ||
| Q3 25 | $1.6B | $25.5B | ||
| Q2 25 | $1.6B | $25.5B | ||
| Q1 25 | $1.6B | $25.0B | ||
| Q4 24 | $1.7B | $25.6B | ||
| Q3 24 | $1.6B | $25.5B | ||
| Q2 24 | $1.1B | $21.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | — |
| Free Cash FlowOCF − Capex | $122.4M | — |
| FCF MarginFCF / Revenue | 59.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $123.0M | $432.4M | ||
| Q3 25 | $78.4M | $157.1M | ||
| Q2 25 | $72.4M | $123.9M | ||
| Q1 25 | $55.4M | $47.3M | ||
| Q4 24 | $84.6M | $283.8M | ||
| Q3 24 | $-9.0M | $108.3M | ||
| Q2 24 | $67.4M | $54.3M |
| Q1 26 | — | — | ||
| Q4 25 | $122.4M | — | ||
| Q3 25 | $78.3M | — | ||
| Q2 25 | $72.4M | — | ||
| Q1 25 | $54.6M | — | ||
| Q4 24 | $84.1M | — | ||
| Q3 24 | $-9.2M | — | ||
| Q2 24 | $67.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | 59.6% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 46.2% | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 46.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.25× | 4.35× | ||
| Q3 25 | 2.49× | 1.48× | ||
| Q2 25 | 6.05× | 1.24× | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | 4.67× | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | 2.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
